Abstract: A compound has a tetra-hydroquinoline skeleton, the compound having inhibitory action against ferroptosis, and exerting therapeutic or preventive effect on diseases, disorders or syndromes related to ferroptosis inhibition, such as multiple sclerosis.

Abstract: A therapeutic agent or a preventive agent for alopecia areata has an ROR? antagonistic activity, and, there is a therapeutic agent or a preventive agent for alopecia areata, including a cyclic amine derivative typified by the following compound or a pharmacologically acceptable salt thereof as an active ingredient.

Abstract: A projection display apparatus according to an embodiment of the present disclosure includes: a light source optical system including a light source section, a light conversion section that converts light emitted from the light source section to light having a wavelength band different from a wavelength band of the emitted light, and a cooling section that cools the light conversion section; and an external casing that houses the light source optical system and has an air inlet and an air outlet that form an airflow path in a linear shape. The light source section and the light conversion section are disposed on the airflow path, and the cooling section is disposed at a position shifted from the airflow path.

Abstract: A cyclic amine derivative represented by general Formula (I): wherein R1 represents an alkyl group having 1 to 3 carbon atoms; A represents a group represented by general Formula (II-1), (II-2), or (II-3): R2 represents a hydrogen atom or a halogen atom; R3 represents an aryl group or a cycloalkyl group having 4 to 6 carbon atoms, wherein any 1 or 2 hydrogen atoms of the aryl or cycloalkyl group represented by R3 may be each independently substituted with an alkyl group having 1 to 3 carbon atoms or an alkyloxy group having 1 to 3 carbon atoms, and wherein any 1 to 3 hydrogen atoms of the alkyl or alkyloxy group having 1 to 3 carbon atoms which can be a substituent of the aryl or cycloalkyl group may be each independently substituted with a halogen atom; n represents 1 or 2; or a pharmacologically acceptable salt thereof.

Abstract: A projection display apparatus according to an embodiment of the disclosure includes: a projection unit including a light source section, a wavelength converter including a discoid member and a motor section, the discoid member including a wavelength conversion layer that converts outgoing light from the light source section to light having a wavelength range different from that of the outgoing light, and the motor section rotating the discoid member, and a spatial modulation element that generates image light by modulating light from the light source section and the wavelength converter on the basis of an inputted image signal; and a control unit that controls intensity of the outgoing light emitted from the light source section and a number of rotation of the discoid member in a state where the image light is generated by the spatial modulation element.

Abstract: A light source apparatus including a light source section including one or more solid light sources capable of emitting light of a predetermined wavelength band as incident light; a light outputting section including a light emitting body to be excited by incident light from the light source section and to emit visible light having a wavelength band longer than a wavelength of the incident light, the light outputting section being capable of emitting synthetic light containing light having the predetermined wavelength band and visible light from the light emitting body; and a housing holding the light source section and the light outputting section, the housing including an inlet and an outlet formed not to face a light path of the incident light from the light source section to the light outputting section.

Abstract: A therapeutic agent or a preventive agent for alopecia areata has an ROR? antagonistic activity, and, there is a therapeutic agent or a preventive agent for alopecia areata, including a cyclic amine derivative typified by the following compound or a pharmacologically acceptable salt thereof as an active ingredient.

Abstract: To provide an image projection apparatus that is able to efficiently cool an inside of a housing. There is provided an image projection apparatus including: an air intake port that is provided in a housing and through which air is caused to flow into an inside of the housing; and an air discharge port that is provided in the housing and through which air inside the housing is discharged. The image projection apparatus includes an air exhaust flow path in which air that has flowed into the inside of the housing from the air intake port is caused to pass through a heat generation component having a highest temperature, at an end of the passing through, among a plurality of heat generation components provided inside the housing, and is discharged from the air discharge port.

Abstract: A projection display apparatus according to an embodiment of the present disclosure includes: a light source optical system including a light source section, a light conversion section that converts light emitted from the light source section to light having a wavelength band different from a wavelength band of the emitted light, and a cooling section that cools the light conversion section; and an external casing that houses the light source optical system and has an air inlet and an air outlet that form an airflow path in a linear shape. The light source section and the light conversion section are disposed on the airflow path, and the cooling section is disposed at a position shifted from the airflow path.

Abstract: A compound has inhibitory activity on Discoidin Domain Receptor 1. The compound includes a urea derivative represented by the formula below or a pharmaceutically acceptable salt thereof.

Abstract: A projection display apparatus according to an embodiment of the disclosure includes: a projection unit including a light source section, a wavelength converter including a discoid member and a motor section, the discoid member including a wavelength conversion layer that converts outgoing light from the light source section to light having a wavelength range different from that of the outgoing light, and the motor section rotating the discoid member, and a spatial modulation element that generates image light by modulating light from the light source section and the wavelength converter on the basis of an inputted image signal; and a control unit that controls intensity of the outgoing light emitted from the light source section and a number of rotation of the discoid member in a state where the image light is generated by the spatial modulation element.

Abstract: A compound has retinoid-related orphan receptor ? antagonist activity and shows a therapeutic effect or a preventive effect on autoimmune diseases such as multiple sclerosis or psoriasis or allergic diseases, including allergic dermatitis or the like, such as contact dermatitis or atopic dermatitis. The cyclic amine derivative is represented by the formula or a pharmacologically acceptable salt thereof.

Abstract: To provide an image projection apparatus that is able to efficiently cool an inside of a housing. There is provided an image projection apparatus including: an air intake port that is provided in a housing and through which air is caused to flow into an inside of the housing; and an air discharge port that is provided in the housing and through which air inside the housing is discharged. The image projection apparatus includes an air exhaust flow path in which air that has flowed into the inside of the housing from the air intake port is caused to pass through a heat generation component having a highest temperature, at an end of the passing through, among a plurality of heat generation components provided inside the housing, and is discharged from the air discharge port.

Abstract: A compound has inhibitory activity on Discoidin Domain Receptor 1. A urea derivative is represented by the formula (I) or a pharmaceutically acceptable salt thereof: wherein, R1 is trifluoromethyl, trifluoromethoxy, or pentafluorosulfanyl; each R2 is independently a hydrogen atom or methyl which is optionally substituted by one hydroxyl or one saturated heterocyclyl having four to six ring-forming atoms; R3 is a hydrogen atom, halogen atom, C1-C3 alkyl, saturated heterocyclyl having four to six ring-forming atoms and optionally having an oxo group, or R5O—; and R4 is phenyl, pyridyl, pyridazinyl, or pyrimidinyl, which phenyl, pyridyl, pyridazinyl, or pyrimidinyl is optionally substituted by one R6.

Abstract: A light source apparatus including a light source section including one or more solid light sources capable of emitting light of a predetermined wavelength band as incident light; a light outputting section including a light emitting body to be excited by incident light from the light source section and to emit visible light having a wavelength band longer than a wavelength of the incident light, the light outputting section being capable of emitting synthetic light containing light having the predetermined wavelength band and visible light from the light emitting body; and a housing holding the light source section and the light outputting section, the housing including an inlet and an outlet formed not to face a light path of the incident light from the light source section to the light outputting section.

Abstract: A compound has inhibitory activity on Discoidin Domain Receptor 1. The compound includes a urea derivative represented by the formula below or a pharmaceutically acceptable salt thereof.

Abstract: A compound has retinoid-related orphan receptor ? antagonist activity and shows a therapeutic effect or a preventive effect on autoimmune diseases such as multiple sclerosis or psoriasis or allergic diseases, including allergic dermatitis or the like, such as contact dermatitis or atopic dermatitis. The cyclic amine derivative is represented by the formula or a pharmacologically acceptable salt thereof.

Abstract: A light source apparatus including a light source section including one or more solid light sources capable of emitting light of a predetermined wavelength band as incident light; a light outputting section including a light emitting body to be excited by incident light from the light source section and to emit visible light having a wavelength band longer than a wavelength of the incident light, the light outputting section being capable of emitting synthetic light containing light having the predetermined wavelength band and visible light from the light emitting body; and a housing holding the light source section and the light outputting section, the housing including an inlet and an outlet formed not to face a light path of the incident light from the light source section to the light outputting section.

Abstract: A compound has inhibitory activity on Discoidin Domain Receptor 1. A urea derivative is represented by the formula (I) or a pharmaceutically acceptable salt thereof: wherein, R1 is trifluoromethyl, trifluoromethoxy, or pentafluorosulfanyl; each R2 is independently a hydrogen atom or methyl which is optionally substituted by one hydroxyl or one saturated heterocyclyl having four to six ring-forming atoms; R3 is a hydrogen atom, halogen atom, C1-C3 alkyl, saturated heterocyclyl having four to six ring-forming atoms and optionally having an oxo group, or R5O—; and R4 is phenyl, pyridyl, pyridazinyl, or pyrimidinyl, which phenyl, pyridyl, pyridazinyl, or pyrimidinyl is optionally substituted by one R6.

Abstract: An image display apparatus includes a laser light source, a light modulator, a first sensor, a second sensor, a third sensor, and circuitry. The light modulator generates an image based on light from the laser light source. The first sensor measures a first temperature in a vicinity of an air inlet of a housing of the image display apparatus. The second sensor measures a second temperature associated with the laser light source. The third sensor measures a third temperature associated with the light modulator. The circuitry is configured to control output of the laser light source based on at least one of the first, second, or third temperatures.